Published in Health Business Week, January 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Indevus Pharmaceuticals.
Report 1: Indevus Pharmaceuticals, Inc., (IDEV) announced the signing of the definitive supply agreement with Schering, AG, Germany for NEBIDO, a long-acting, injectable testosterone preparation for the treatment of male hypogonadism.
In July 2005, Indevus licensed the exclusive U.S. rights to NEBIDO from Schering, AG. NEBIDO, which was approved and launched in Europe last year, is the first injectable product for treating hypogonadism requiring...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.